Durable Improvements Observed With Long-Term Guselkumab in Psoriatic Arthritis Trial
The DISCOVER-2 trial included 739 biologic-naïve adults with active psoriatic arthritis who were treated and followed for approximately 2 years.
The DISCOVER-2 trial included 739 biologic-naïve adults with active psoriatic arthritis who were treated and followed for approximately 2 years.
Zolgensma is an adeno-associated virus vector-based gene therapy.
The phase 3 ATOM study evaluated the efficacy and safety of abaloparatide in 228 men with osteoporosis.
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
The update is based on data from an open-label, single-arm histomorphometry study.
The network meta-analysis compared the effects of 9 osteoporosis drugs on BMD.
The revisions are based on a completed review of a large randomized safety clinical trial, which included 4362 patients with rheumatoid arthritis.
EDG-5506 is a selective, small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers.
The indication for adult upper limb spasticity treatment now includes elbow and forearm muscles, intrinsic hand muscles, and thumb muscles.
Small increases in the risk for statin-associated muscle symptoms were observed for patients on high-intensity therapy.